IP Library Granted Patent US 9,808,465
Granted Patent B2
US 9,808,465 · App. 14/859,013 · Granted Nov 7, 2017

Emulsion formulations of aprepitant

Inventors: Thomas B. Ottoboni (Belmont, CA); Han Han (Mountain View, CA)
Assignee: Heron Therapeutics, Inc.
A61K31/5377A61K9/0019A61K9/0024A61K9/107A61K31/573A61K47/10A61K47/12A61K47/18A61K47/24A61K47/26A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,808,465
App. No.
14/859,013
Granted
Nov 7, 2017
Kind
B2
Abstract

Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Claims (20)

1. A method for preventing or treating a subject at risk of or suffering from emesis, comprising administering to the subject a composition comprising an injectable physically stable emulsion wherein the emulsion comprises:

aprepitant;

11 wt/wt % to 15 wt/wt % of an emulsifier; an oil;

a co-emulsifier which is an alcohol; a tonicity modifier; a pH modifier; and water;

wherein the ratio of emulsifier:aprepitant ranges from about 18:1 to 22:1, and

wherein the pH of the emulsion ranges from about 7.5 to 9.0.

2. The method according to claim 1 , wherein the emesis is induced by chemotherapy.

3. The method according to claim 1 , wherein the emesis is induced by highly emetogenic chemotherapy.

4. The method according to claim 1 , wherein the ratio of the oil to the aprepitant within the oil phase of the emulsion ranges from about 10:1 to 15:1 (wt/wt %).

5. The method according to claim 1 , wherein the ratio of the emulsifier to the oil ranges from about 1:1 to 3:1 (wt/wt %).

6. The method according to claim 5 , wherein the emulsifier in the emulsion is a phospholipid.

7. The method according to claim 1 , wherein the emulsion further comprises dexamethasone sodium phosphate, wherein the dexamethasone sodium phosphate is present in the aqueous phase.

8. The method according to claim 1 , wherein the emulsifier in the emulsion is an egg lecithin.

9. The method according to claim 1 , wherein the pH modifier in the emulsion is sodium oleate.

10. The method according to claim 1 , wherein the emulsion further comprises a buffer.

11. The method according to claim 10 , wherein the buffer is Tris buffer.

12. The method according to claim 1 , wherein the oil in the emulsion is soybean oil.

13. The method according to claim 1 , wherein the alcohol in the emulsion is ethanol.

14. The method according to claim 13 , wherein the ethanol is present in the emulsion at less than 10 wt/wt %.

15. The method according to claim 13 , wherein the tonicity modifier in the emulsion is sucrose.

Assignments (4)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 9, 2023
From: HERON THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 064546/0453 →
RELEASE OF SECURITY INTEREST Recorded Mar 25, 2021
From: TANG CAPITAL PARTNERS, LP
To: HERON THERAPEUTICS, INC.
Reel/Frame 055725/0523 →
SECURITY INTEREST Recorded Aug 30, 2016
From: HERON THERAPEUTICS, INC.
To: TANG CAPITAL PARTNERS, LP
Reel/Frame 039590/0239 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2016
From: OTTOBONI, THOMAS B.; HAN, HAN
To: HERON THERAPEUTICS, INC.
Reel/Frame 038448/0958 →
Continuity (2)
Provisional Application 62052948 · Sep 19, 2014
Related Publication 20160082013A1 · Mar 24, 2016